CRBP
NASD Corbus Pharmaceuticals Holdings Inc$6.13 ↑ +0.00 (+0.00%) Trading Up from the previous close of $6.13
- YTD change
- -24.69%
- vs 20-day SMA
- -20.69%
- vs 200-day SMA
- -31.68%
Price ranges
Price & Performance
-4.01 (-39.55%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 98.1% away from all-time highs of $323.40
- CRBP is down 25% since the beginning of the year
- CRBP is down 59% over the past 12 months
- CRBP is down 47% over the past 1 month
- 14% of all CRBP investors are betting against CRBP
CRBP reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -57.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -14.15%
- vs 8-day SMA
- -11.11%
No alerts for CRBP in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
